Hepatitis B Quick Facts
- Hepatitis B (HBV) is a viral infection that infects the liver and requires direct contact with infected blood or other body fluids for transmission. Most acute hepatitis B infections do not persist but if the infection lasts 6 months or longer, it could lead to chronic liver disease, liver cancer and death.1
- Hepatitis B is not common in childhood in the U.S. and is not highly contagious in the same way that common childhood diseases like pertussis and chicken pox are contagious. In the U.S., hepatitis B is primarily an adult disease (ages 20-50) but the virus also can be transmitted from an infected mother to her newborn baby. Most people do not experience any symptoms during acute infection but may have symptoms, such as yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain.2,3
- While hepatitis B was not prevalent in the U.S. before childhood vaccination campaigns were introduced in 1991, historically it has been endemic in Asia and Africa. In 1991, there were 18,003 cases of hepatitis B reported in the U.S. out of a total U.S. population of 248 million. In 1996, there were 10,637 cases of hepatitis B reported in the U.S. with 279 cases reported in children under the age of 14.4
- Worldwide, hepatitis B is the cause of up to 80 percent of liver cancer and an estimated 686,000 people die each year from acute or chronic hepatitis B around the world.5,6
- In the U.S., individuals at highest risk for hepatitis B infection are those, who engage in risky behaviors such as illegal IV drug use, prostitution, men who have sex with men, heterosexuals with multiple sexual partners and people who have received blood transfusions using infected blood.7 Healthcare workers, who are exposed to infected blood or body fluids of patients through contact with needles or medical devices used on patients, or when breaches in proper hygiene and/or infection control practices occur, are at high risk for becoming infected with hepatitis B.8 In 2015, there were 3,370 acute cases of hepatitis B reported in the U.S.9
Hepatitis B Vaccine
- There are five recombinant hepatitis B vaccines approved by the FDA for use in the U.S.: Engerix-B; Recombivax HB; Twinrix (combined with hepatitis A); and Pediarix (combined with diphtheria and tetanus toxoids, acellular pertussis adsorbed, and inactivated poliovirus).10 The fifth, Comvax (combined with Haemophilus Influenza Type B (HIB) and Meningococcal Protein) is an approved vaccine but production of the vaccine was discontinued in December 2014.11 The recombinant hepatitis B vaccine is created through genetic engineering of DNA by inserting a segment of the viral gene in a yeast cell.12
- The CDC recommends that all infants be vaccinated with three doses of hepatitis B vaccine beginning at 12 hours of age with the last dose given before 18 months of age to prevent transmission by an infected mother to her newborn.13 The CDC also recommends hepatitis B vaccination for adults with diabetes; household and sexual contacts of people with chronic hepatitis B infection; healthcare workers; people at increased risk for hepatitis B virus exposure due to occupational, behavioral, or medical factors; and international travelers to countries with high or intermediate hepatitis B infection rates. 14
- The primary reason that the CDC recommended hepatitis B vaccination for all newborns in the United States in 1991 is because public health officials and doctors could not persuade adults in high risk groups (primarily IV drug users and persons with multiple sexual partners) to get the vaccine.15,16 ,17
- Despite hepatitis B affecting mainly adults (aged 20 to 50), by 2014, only 24.5 percent of U.S. adults over 19 years of age had received the vaccine. Further, only 60.7 percent of U.S. health care workers in 2014 had been vaccinated for hepatitis B.18
- As of August 2017, there had been 861 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following hepatitis B containing vaccinations, including 89 deaths and 772 serious injuries.19
- Using the MedAlerts search engine, as of May 31, 2017 there had been a total of 83,585 adverse events following hepatitis B containing vaccinations reported to the federal Vaccine Adverse Events Reporting System (VAERS) since 1990, and 61,825 of the adverse events were associated with hepatitis B vaccine alone (not combined with other vaccines). There had been 16,435 serious adverse events reported to the Vaccine Adverse Events Reporting System (VAERS) in connection with Hepatitis B containing vaccines since 1990. Approximately 55% of those serious Hepatitis B vaccine-related adverse events occurring in children under 3 years old. Of these Hepatitis B-vaccine related adverse event reports to VAERS 1,857 were deaths, with 82%, or 1,524, of the deaths occurring in children under three years of age.
Food & Drug Administration (FDA)
Search for Vaccine Reactions
NVIC hosts MedAlerts, a powerful VAERS database search engine. MedAlerts examines symptoms, reactions, vaccines, dates, places, and more.
Reporting a Vaccine Reaction
Since 1982, the NVIC has operated a Vaccine Reaction Registry, which has served as a watchdog on VAERS. Reporting vaccine reactions to VAERS is the law. If your doctor will not report a reaction, you have the right to report a suspected vaccine reaction to VAERS.
Vaccine Reaction Symptoms & Ingredients
Our Ask 8, If You Vaccinate webpage contains vaccine reaction symptoms and more. Calculate vaccine ingredients for potential toxic exposures & print a vaccination plan with the Vaccine Ingredients Calculator.
Centers for Disease Control (CDC)
IMPORTANT NOTE: NVIC encourages you to become fully informed about Hepatitis B and the Hepatitis B vaccine by reading all sections in the Table of Contents , which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.
« Return to Vaccines & Diseases Table of Contents
1 CDC. Viral Hepatitis - Hepatitis B information.
2 World Health Organization (WHO). Media Centre Fact Sheets. Hepatitis B. July 2017.
3 CDC. Hepatitis B Information for Health Professionals. Hepatitis B Vaccination FAQs for Health Professionals. Revised Aug. 4, 2016.
4 CDC. Summary of Notifiable Diseases, United States 1996. Table 2 – Notifiable Diseases – Summary of reported cases, United States 1991 and 1996. MMWR Oct. 31, 1997; 45(53): 1-89.
5 World Health Organization. Media Centre Fact Sheets. Hepatitis B.
6 CDC. Vaccines: The Pink Book. Hepatitis B. 13th Edition. 2015.
7 CDC. Hepatitis B FAQs for Health Professionals: Who is at risk for HBV infection? Revised May 31, 2015.
8 Medscape. Wassem, M, Body Fluid Exposures. Revised Jul. 12, 2017.
9 CDC. Surveillance for Viral Hepatitis – United States, 2015. Hepatitis B. Table 3.1 Reported cases of acute hepatitis B, national and by state or jurisdiction – United States, 2011-2015. Revised Jun. 19, 2017.
CDC. Viral Hepatitis – Statistics and Surveillance. May 19 2016.
10 FDA. Vaccines, Blood & Biologics. Complete List of Vaccines Licensed for Immunization and Distribution in the U.S. Jan 25, 2017
11 CDC. Current Vaccine Shortages & Delays. Revised Aug. 15, 2017.
12 CDC. Vaccines: The Pink Book. Principles of Vaccination. 13th Edition. 2015.
13 CDC. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus: Infection in the United States – Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children and Adolescents. MMWR 54(RR16):1-23, Dec 23, 2005.
14 CDC. Vaccines. Recommended Adult Immunization Schedule for Adults Aged 19 years or Older, by Vaccine and Age Group - United States 2016. Revised Feb. 6, 2017.
15 Kasper D, Fauci A, Longo D, et al. Disorders of the Gastrointestinal System: Prophylaxis: Hepatitis B. Harrison’s Principles of Internal Medicine 16th Edition. 2005. pp 1836-1837.
16 Viral Hepatitis Prevention Board. Antwerp VHPB Report. Editorial. Control of viral hepatitis in Europe. Viral Hepatitis, 1996, 4(2).
17 CDC. Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Nov. 22, 1991, 40(RR-13);1-19
18 CDC. Surveillance of Vaccination Coverage Among Adult Populations – United States 2014 MMWR Feb. 5, 2016, 65(1);1–36
19 DHHS. Petitions Filed, Compensated and Dismissed by Alleged Vaccine, Since the Beginning of the VICP 10/01/1988
through 08/01/2017. HRSA Aug. 1, 2017.